# Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Source: https://onco.cc/trials/nct07339059/  
OnCo record `nct07339059` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of sacituzumab govitecan, atezolizumab and durvalumab in lung cancer, run by Bindu R Potugari, now recruiting.

## Summary

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer is a phase 2, interventional study registered as NCT07339059 by Bindu R Potugari, with a registry enrolment figure of 35 participants, started 2026-05-14 and due to reach its primary completion in 2029-02-01. Interventions recorded: Sacituzumab govitecan; Atezolizumab; Durvalumab. Conditions listed: Small Cell Lung Cancer ( SCLC ); Extensive Stage Small Cell Lung Cancer (ES-SCLC). Primary outcome: Disease Control. Lung eligibility wording from the registry: "* Participants must have a histologically or cytologically confirmed diagnosis of small cell lung cancer (SCLC) and extensive stage at diagnosis or locally advanced disease and unable to receive curative intent radiation". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07339059
- Phase: 2
- Setting: Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
- Sponsor: Bindu R Potugari
- Enrolled: 35

## Sources

- ClinicalTrials.gov NCT07339059: https://clinicaltrials.gov/study/NCT07339059

## Connected records

- cancers: [Extensive-stage small-cell lung cancer](https://onco.cc/cancers/extensive-stage-sclc/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Durvalumab](https://onco.cc/drugs/durvalumab/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07339059.json